Mandate

Vinge advises Epsilon’s owner Danir in connection with Epsilon’s merger with ÅF

October 18, 2012

Vinge is advising Danir, which is owned by Dan Olofsson, in connection with the merger of Danir’s subsidiary, Epsilon, with ÅF. The merger will be effected through ÅF acquiring all of the shares in Epsilon from Danir. The merger is driven by a strong industrial logic, since ÅF and Epsilon largely share a common culture and complement each other in terms of technical expertise, service offering, customer base and geographical presence. Over the last twelve months, the new ÅF Group would have had annual sales of approximately SEK 7.8 billion.

The consideration consists of an initial purchase price of approximately SEK 1,700 million (enterprise value), consisting partly of SEK 850 million in cash and partly of 5,985,915 newly issued class B shares in ÅF. There will also be an additional purchase price amounting to a maximum of SEK 1,100 million. The completion of the Transaction is conditional upon approval by the relevant competition authorities and approval by the ÅF Extraordinary General Meeting, which will be held on 19 November 2012.

Vinge’s team advising Danir consists of partners Peter Oscarsson, Jesper Ottergren and Pär Remmelid and associate Karolina Tjärnberg Jansson.

Related

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026